Literature DB >> 10363354

Molecular pathology of Luft disease and structure and function of mitochondria.

F S Sjöstrand1.   

Abstract

Luft disease, studied in detail by Luft et al. (1962) is characterized clinically by hypermetabolism and consequent abnormal transpiration. In their study, Luft and coworkers revealed that the hypermetabolism is caused by extensive uncoupling of mitochondrial respiration in skeletal muscle tissue. They also discovered that the muscle mitochondria had been structurally modified with the cristae assuming a zig-zag conformation. The mitochondrial enzymes functioned normally, the abnormality being confined to the extensive uncoupling of respiration. In an earlier study (Sjöstrand et al., 1988) it was revealed that the zig-zag conformation is caused by removal of some tricarboxylic acid cycle enzymes from the cristae, exposing the interior of the cristae to the matrix fluid. Applying a coupling theory proposed by Sjöstrand (1990, 1991), leakage of protons from the cristae should impair coupling of respiration and ATP synthesis. The structural damage is conceived of to be caused by a genetic defect preventing proper aggregation of the enzyme molecules in the cristae. Luft disease may therefore be the first known disease caused primarily by a structural disorder at the molecular level. The symptoms of the disease reveal the importance of the compact and ordered aggregation of the enzyme molecules in the cristae for coupling of respiration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10363354

Source DB:  PubMed          Journal:  J Submicrosc Cytol Pathol        ISSN: 1122-9497


  2 in total

1.  Overexpression of peroxisome proliferator-activated receptor gamma co-activator-1alpha leads to muscle atrophy with depletion of ATP.

Authors:  Shinji Miura; Eriko Tomitsuka; Yasutomi Kamei; Tomomi Yamazaki; Yuko Kai; Mayumi Tamura; Kiyoshi Kita; Ichizo Nishino; Osamu Ezaki
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

2.  IEX-1 targets mitochondrial F1Fo-ATPase inhibitor for degradation.

Authors:  L Shen; L Zhi; W Hu; M X Wu
Journal:  Cell Death Differ       Date:  2008-12-19       Impact factor: 15.828

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.